Baillie Gifford & Co. Sells 308,742 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Baillie Gifford & Co. lessened its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 71.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,855 shares of the company's stock after selling 308,742 shares during the quarter. Baillie Gifford & Co. owned 0.20% of Health Catalyst worth $992,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in HCAT. Summit Global Investments grew its holdings in shares of Health Catalyst by 8.1% in the 3rd quarter. Summit Global Investments now owns 66,544 shares of the company's stock worth $542,000 after purchasing an additional 4,991 shares during the last quarter. Impax Asset Management Group plc grew its holdings in Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company's stock worth $20,793,000 after acquiring an additional 360,201 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock worth $96,000 after acquiring an additional 2,064 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Health Catalyst during the third quarter worth approximately $897,000. Finally, Nepsis Inc. grew its stake in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company's stock valued at $17,131,000 after purchasing an additional 851,448 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Insider Buying and Selling at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares of the company's stock, valued at approximately $1,062,018.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company's stock, valued at $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of the company's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company's stock, valued at approximately $1,062,018.64. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,068 shares of company stock valued at $257,555 in the last quarter. 2.50% of the stock is currently owned by insiders.

Health Catalyst Stock Performance

Shares of HCAT traded down $0.13 during midday trading on Thursday, reaching $8.53. The stock had a trading volume of 154,498 shares, compared to its average volume of 561,104. The firm has a market cap of $519.05 million, a PE ratio of -6.41 and a beta of 1.32. The firm has a 50 day simple moving average of $8.13 and a 200-day simple moving average of $7.20. Health Catalyst, Inc. has a one year low of $5.42 and a one year high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The company's revenue for the quarter was up 3.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

HCAT has been the subject of several recent research reports. Stephens boosted their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Thursday. Cantor Fitzgerald reissued an "overweight" rating and set a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Piper Sandler reduced their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an "overweight" rating on the stock in a research note on Monday, August 26th. Evercore ISI upped their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. Finally, Royal Bank of Canada increased their price target on Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst currently has an average rating of "Moderate Buy" and an average price target of $11.71.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.